Objectives. This study evaluated community pharmacists' confidence in their knowledge regarding the advances in the human genome project (HGP) and determined their requirements for education and training on this subject. Methods. A survey was administered to community pharmacists (N=377) working in the Houston Metropolitan Area using a convenient sampling process. Results. In general, respondents indicated that their confidence in knowledge regarding the HGP, genetic testing, and pharmacogenomics was less than 50%. Overall, pharmacists believe that they should receive training on the proper handling of drugs developed from the advances in the HGP. In addition, they agreed that pharmacists should be required to take at least 2 CE credits on human genetics and that pharmacy schools should include information regarding the advances in the HGP in their curriculum. Conclusions. Pharmacist should be educated in the advances of the HGP and the implications of such advances on their professional responsibilities. Colleges of pharmacy across the nation should explore ways to incorporate information regarding the HGP in their curriculums. Furthermore, opportunities to provide continuing education (CE) credits should be explored by various pharmacy organizations.
INTRODUCTION
The basic idea of the Human Genome Project (HGP) is to map the sequence of the human genome. The results of the HGP are expected to lead to new discoveries in medicine and revolutionize the care provided by health professionals. 1, 2 Clearly, these discoveries may change the practice of pharmacy. In today's practice, the role of the pharmacist is to improve medication use among patients and help reduce the cost of health care. 1 Pharmacists are well positioned to play an important role in selecting appropriate drug therapies based on a patient's genetic profile. 3, 4 In addition, they can advocate policies and procedures to prevent unauthorized disclosure of genetic information. 3 The purpose of this study was to evaluate community pharmacists' confidence in their knowledge regarding the human genome project, In recent literature, there has been concern about the ethical, social, and legal issues raised by the HGP and its impact on the health care system. [5] [6] [7] [8] [9] [10] [11] As information regarding the human genome increases, pharmacists and other health care providers will be challenged to keep pace with the knowledge and its many implications for patient care and welfare. 3 In order to be knowledgeable in this new field, pharmacists must be trained and educated regarding genetics and gene therapy to help them perform their future professional duties.
The Human Genome Project (HGP) started in 1990 as an international effort to map and sequence all the genes in the human body. The US Department of Energy (DOE) and the National Institute of Health (NIH) coordinate the US HGP effort. 12 Although completion of the HGP was originally expected to take 15 years, it was designed to be completed within 10 years, which now appears possible thanks to the rapid advances in sequencing technology. 13 The mapping of the human ge-nome was completed in June 2000. [14] [15] [16] The HGP has made it possible for researchers to identify genes that contribute to the development of hereditary diseases. 17 Now that genome-based preventive medicine is a reality, the focus of medicine will be on prevention rather than treatment of diseases. 17 Apart from revolutionizing the treatment of diseases (a respite for people suffering from previously incurable conditions), findings from the HGP will be instrumental in shifting the focus of medicine to prevention.
Advances in the HGP have provided new information that has had a significant impact on biomedical research, the practice of medicine, and the education of the health professionals regarding the HGP. This constant flow of new information has made it necessary for health care professionals to be aware of genetic information and technologies. The DOE and NIH established the Ethical, Legal, and Social Implications (ELSI) program to investigate issues surrounding the HGP. 18 From the time of its conception, 3% to 5% of the HGP's annual budget has been allocated for the study of ethical, legal, and social issues involving the HGP. 2 The ELSI Research Planning and Evaluation Group (ERPEG) was formed under the ELSI program. 18 The ERPEG-funded surveys have revealed that neither the population at large nor health care professionals are knowledgeable about genetics, genetic technologies, and the possible ethical, legal, and social implications of having access to genetic information. 19 The ERPEG recommended that health professionals have the required knowledge, skills, and resources to successfully incorporate new technologies and information into the prevention, diagnosis, and treatment of disease. Without knowledgeable health professionals, the potential benefit of advances in genetics research will not be fully realized.
The ERPEG recommended specific issues that needed to be addressed. According to the ERPEG, health professionals, public educators, and policymakers, as well as the general public, should receive information regarding genetics, genetic testing and counseling, genetic disorders that cause both physical and mental disabilities, and possible misinterpretations or misuse of genetic information. The ERPEG also recommended studying the advantages and disadvantages of various approaches for educating the public, patients and health professionals.
Genome centers all over the world are using the advances in the HGP to identify and characterize human genes and develop applications. 20 Identification of the entire genome has led to a better understanding of genetic diseases and resulted in many new applications for this knowledge. Some of these applications have included gene therapies and the development of new drugs. Identification of a disease would be based upon genetic defects that are present at birth rather than on disease symptoms, which may not develop until later in life. 3 This change in the strategy for diagnosing and treating patients may require more precise judgment from health care providers regarding drug therapy decisions. As pharmacists in the future tailor drug therapy according to each patient's needs, it is vital that pharmacists stay abreast of developments in the HGP. 4, [21] [22] [23] Pharmacogenomics, the study of genetic factors that influence drug efficacy and toxicity, is a completely new field of knowledge, and the pharmacist must take a dynamic role in its development. 24, 25 The Council on Professional Affairs of the American Society of HealthSystem Pharmacists (ASHP) notes in one of its policy recommendations that practitioners require education so that they can assume leadership roles in pharmacogenomics within their health systems. 21 The ASHP has recommended that pharmacogenomics and its application to therapeutic decision making should be integrated into the curricula of pharmacy schools. 21 Other organizations, such as the American Pharmaceutical Association (APhA) in its 1999-2000 policy committee report on pharmacogenomics, recommend educational efforts be made to prepare pharmacists and pharmacy students to manage the use of new products as a result of findings of the HGP.
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With more and more information becoming available about the human genome, pharmacists and other health care providers will be increasingly challenged to keep pace with the knowledge and its many implications for patient care and welfare. 3 Pharmacists must be trained and educated regarding genetics and gene therapy in order for them to perform their professional duties. As applications of discoveries in the HGP become common, drug selection will depend on the appropriate choice and interpretation of diagnostic tests that are crucial in making drug therapy decisions and will further enhance the pharmacist's role in patient care. 22 Community pharmacy has grown rapidly during the past 5 years, using advances in new technology to provide the best possible care for patients. The activities of pharmacists are also changing as their practices evolve. 27 The advances in the knowledge of human genetics are also expected to impact the practice of pharmacy in a major way. 23 As information is gathered on how genetic factors affect diseases, pharmacists will need to become knowledgeable and stay abreast of the issues surrounding pharmacogenomics. 8 The advent of the HGP and the advances resulting from its findings raise several questions. Are pharmacists prepared for the new discoveries in medicine? Do pharmacists have the knowledge and skills to administer these new drugs? What kind of educational and training requirements will the pharmacist need?
There is limited knowledge and a lack of primary literature evaluating knowledge of health care providers regarding the HGP. Hence, the objective of this study was to determine the confidence that community pharmacists' had in their knowledge of the HGP, genetic testing, and pharmacogenomics. The study also investigated the opinions of pharmacists on various issues regarding the education and training needed to keep up with the advances in human genetic technology.
METHODS
A cross-sectional study was conducted to assess the study objectives. An overview of the study design can be viewed in Figure 1 . A questionnaire was developed based on an extensive review of the literature regarding the Human Genome Project. The questionnaire is referred to hereafter as the Human Genome Project Questionnaire (HGPQ). Each questionnaire was accompanied by an informed consent document requesting voluntary participation in this project. This project received approval from the Committee for the Protection of Human Subjects at the University of Houston. In this questionnaire, pharmacists' confidence in their knowledge of the Human Genome Project, genetic testing, and pharmacogenomics, was assessed. A rating scale of 0 to 100 was used to evaluate pharmacists' level of confidence in their knowledge on these topics, with 0 indicating no confidence in their knowledge and 100 indicating a high level of confidence in their knowledge. An operational definition of each topic was not provided in the questionnaire, as it would have biased the results. In addition, pharmacists' opinions were sought regarding the current and needed educational and training requirements in pharmacogenetics for pharmacists and technicians. A 5-point Likert scale was used to evaluate this portion of the questionnaire. Participants indicated their level of agreement or disagreement with each of the statements, with 1 indicating "strongly disagree"; 2, "disagree"; 3, "neutral"; 4, "agree"; and 5, "strongly agree." Finally, the questionnaire included questions on demographic information such as age, gender, race, marital status, educational background, and pharmacy practice setting. The questionnaire was field tested by 2 research assistants who performed a pilot study involving 10 pharmacists to help refine questions through item analysis and to provide additional evidence for content validity. After reaching an acceptable threshold of confidence, the developed questionnaire was administered to the pharmacists.
A convenient sampling process was used in selecting pharmacists for this survey. The pharmacists practicing in both chain and independent community pharmacies in the Houston metropolitan area were considered in this study. A total of 97 undergraduate and 3 graduate students were recruited to assist with data collection. Students were assigned a specific geographic area in which they could collect data. Because of the vast number of pharmacies in the Houston area, students were not restricted to visiting only those pharmacies on a particular list. Students visited the pharmacies during normal business hours and requested to speak with the pharmacist in charge at that time. Respecting their busy schedules, the pharmacists were given 3 days to complete the questionnaire. If the pharmacist required more time, they were given 2 additional days to complete the questionnaire. If the pharmacist declined to participate, they were thanked for their time and the students proceeded to the next store in the area. Students were required to collect the surveys from the pharmacists and to monitor data collection. Each student was given only 5 surveys to distribute and collect (500 total surveys distributed). Neither the name of the pharmacist nor any identification information was solicited during the course of this study. However, students did note the address of each pharmacy from which they collected a survey. This information was used to assess sample distribution and to avoid duplication during the data collection process. Completed questionnaires were coded and analyzed using the SAS®8.2 statistical package, SAS Institute Inc, Cary, NC. Descriptive analysis and correlation analysis were performed to assess the study objectives. In addition, where appropriate, t-tests and analysis of variance (ANOVA) were performed to compare the mean scores of the variables measured. All analyses were performed at a significance level of 0.05.
RESULTS
A total of 377 (75.4%) completed surveys were obtained. The average age of the pharmacist was 39.82 (±9.82) years. A higher percentage of the pharmacists who participated were female (59%). A majority of the pharmacists had a Bachelor of Science (BS) degree (78%). As much as 72% of the respondents were pharmacists practicing in a chain pharmacy setting. Race and marital status had no effect on the variables measured (P>0.05). Demographic information regarding the sample can be viewed in Table 1 . A majority of the pharmacists believed that their confidence in their knowledge regarding the HGP, genetic testing, and pharmacogenomics was less than adequate (Table 2) . A frequency distribution of the scores showed that more than 70% of the participants indicated a score below 50% with respect to their level of confidence in their knowledge of the HGP and pharmacogenomics topics. Age was negatively correlated with the participants' confidence in knowledge regarding the HGP, genetic testing, and pharmacogenomics (Table 2 ). Educational background also had a significant impact on their confidence in knowledge scores. Pharmacists with a PharmD indicated significantly higher confidence in their knowledge compared with those with BS degrees (Table 3) . Although, pharmacists in independent settings had slightly higher scores with respect to confidence in their knowledge, only scores of their confidence in knowledge of genetic testing were significantly different between the 2 groups (pharmacists at chain pharmacies indicated a confidence level of 42.9% ±24.69% vs. pharmacists at independent pharmacies who indicated a confidence level of 49.52% ± 24.4%; P< 0.05). No significant difference was found between the 2 groups' with respect to scores for confidence in knowledge regarding the HGP and pharmacogenomics.
Opinions regarding the pharmacists' role and their concern regarding education/training issues can be viewed in Table 4 . Community pharmacists in our study believed that the role of the pharmacist (3.41 ± 0.96), as well as the delivery of pharmaceuticals (3.48 ± 0.83), would change in the future due to advances in human genetics. Scores among practice settings were mixed (Table 4 ). There were significant differences (P< 0.05) in opinions between pharmacists working in chain and independent pharmacies on issues such as increase in workload and special storage requirements for drugs developed as a result of advances in human genetics. Scores on these items were higher for pharmacist practicing in chain pharmacies compared with those of pharmacists practicing in independent pharmacies (Table 4) . Pharmacists in chain settings strongly agreed there is a need to include patients' genetic information in the pharmacy's database in order to improve drug dispensing. Their responses were significantly different from those of pharmacists practicing in independent settings (Table 4) . Pharmacists in both groups agreed that operating costs in pharmacies would increase as a result of advancements in genetics (mean response = 3.64 3.64 ± 0.84). In addition, they believed that information gained from the advances in human genetics could be used to individualize drug dosing (mean response 3.71 ± 0.74) and identify those patients most likely to respond to drug therapy (mean response 3.76 ± 0.73)
Pharmacists in both practice settings did not differ significantly on issues regarding education and training (Table 4) . Pharmacists believed that inclusion of information regarding the HGP in the curriculum of pharmacy schools would be one measure of keeping the future pharmacist abreast of knowledge regarding the HGP (mean response = 3.71 ± 0.88). Moreover, they felt that mandating 2 hours of CE credits on human genetics would prove useful in keeping the pharmacist's knowledge regarding the HGP up to date ( Table 4 ). The pharmacists believed that they should receive training on the proper handling of drugs developed as a result of advances in human genetics (mean response = 3.95 ± 0.71), and that they in turn would have to provide training to technicians (mean response = 3.67 ±0.88). Although pharmacists believed that they would have to spend more time counseling patients on the appropriate use of drugs developed as a result of advances in the HGP (mean response = 3.60 ± 0.87), they also believed education in human genetics would improve the pharmacist's knowledge regarding patient counseling (mean response = 3.71 ± 0.85).
DISCUSSION
Based on the results, community pharmacists in our study indicated they had less than 50% confidence in their knowledge on topics regarding the HGP, genetic testing, and pharmacogenomics. Furthermore they agreed that they needed more information and training on the new advances of the HGP. Though the number of continuing education programs on pharmacogenomics has shown an increase in the recent years, these programs have concentrated on general issues. 11 Pharmacy associations should look more towards specialized Our findings regarding confidence in knowledge of the pharmacists were consistent with those reported by the ERPEG. 19 The ERPEG in its report mentioned that health care professionals are not knowledgeable but need to be knowledgeable about genetic testing and other issues related to the HGP. Age and educational background did affect the pharmacists' scores on confidence in knowledge in our study. In addition, the majority of the pharmacists indicated less than adequate confidence in their knowledge regarding the HGP, genetic testing, and pharmacogenomics. There is a possibility that the pharmacists in the PharmD program were exposed to some topics on the HGP during the extensive clinical rotations completed as part of their pharmacy curriculum, and this was reflected in their slightly higher confidence level in their knowledge. Clearly the same does apply to younger pharmacists too, justifying the significant effect of age on confidence in knowledge. Younger pharmacists who may have graduated more recently could have been exposed to such topics during their clinical rotations, thus justifying higher scores on knowledge. Although, the effect of the pharmacist's age was significant, the Spearman rank correlation coefficients were not very high, indicating that other variables, in addition to age, may play a role in predicting confidence in knowledge, or that the sample size was large enough to account for the variance explained by age.
As new discoveries are made and applications developed as a result of advances in the HGP, understanding how it may affect our professional responsibilities will be critical. In addition, advances in the HGP are expected to lead to the development of a number of new products that may require special delivery systems and have special storage and dispensing requirements. Pharmacist would have to apply the knowledge gained through education and training to ensure effective delivery of these products. In addition to the new drugs developed, pharmacists also will have to keep up with the current pharmacogenomic technology and understand its applications. Participants in our study believed that the advances in the HGP would change the role of pharmacists in the future. Furthermore, they were * Actual statements used on the survey with a 5 point Likert scale, where 1 = strongly disagree and 5 = strongly agree. †Difference between pharmacists' practicing in chain and independent setting, P < 0.05 using t-test.
concerned that new products developed due to advances in the HGP may require special storage conditions, thus leading to increased operating costs. The issue of cost attributable to genetic testing and to products that require specialized storage has been mentioned previously. 28, 29 There is also the possibility that expecting a rapid conversion of many of the genetic discoveries into clinical applications may have prompted the pharmacists in our study to believe that they required training on the proper handling of new drugs.
With the advances in the HGP, the pharmacist will have to spend more time counseling patients and answering complex questions from physicians. The HGP is expected to usher in the era of tailor-made drugs; drugs that will be for a specific person based on their genetic profile. 4, 21, 23, 24 Pharmacists are expected to spend more time counseling and educating the patient on the appropriate use of such products. Community pharmacists in this study also believed they would be spending more time counseling patients. In addition, they believed that information gained from the HGP could be used to individualize drug dosing and identify those patients most likely to respond to drug therapy. Furthermore, they agreed that education on human genetics would help them improve their knowledge regarding patient counseling for specific products.
The rapid increase in the information regarding the HGP may make it difficult for health care professionals and the public at large to keep abreast of the information regarding the new advances in pharmacogenomics. After considering this issue in the year 2000 the ASHP recommended the addition of pharmacogenomics to the curriculum of Pharmacy Schools.
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Pharmacists in our study made the same recommendation. In addition, pharmacists in our study indicated that they should be required to take at least 2 CE credits on such topics. It is encouraging to see that some pharmacy schools have incorporated information on pharmacogenomics into their curricula. 11 However, this is not the case universally, and only a limited number of schools have placed emphasis on the topic of pharmacogenomics.
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The pharmacy schools at the University of Wisconsin and the University of North Carolina at Chapel Hill recently presented their courses at the AACP 2002 annual convention. These institutions have modeled their courses according to the recommendations of the National Coalition for Health Professional Education in Genetics (NCHPEG). 30, 31 The American Medical Association, the American Nurses Association, and the National Human Genome Research Institute established the NCHPEG in 1996. 32 The mission of NCHPEG is to promote the education of health professionals and improve access to information regarding advances in human genetics to improve the health care of the nation. This organization is potentially a good resource for pharmacists to keep up with new developments and current trends in pharmacogenomics. 32 The NCHPEG has established core competencies in the field of genetics that are essential for all health care professionals. Competencies in these areas represent the minimum knowledge and skills pharmacists' need, as well as the confidence required to provide patient care.
Pharmacists must acquire CE credits as a requirement to maintain licensure. State boards of pharmacy should consider issues that would arise with the new trend in drug discoveries and mandate certain requirements with respect to CE credits. During the 1980s, a few states (eg, Florida and Kentucky) mandated that pharmacists earn special CE credits for HIV/AIDS. Given that topics on the HGP and pharmacogenomics are as "new" to pharmacists as HIV and AIDS were in the 1980s when such requirements were initiated, perhaps states boards should consider replacing the HIV/AIDS requirements with requirements for HGP or pharmacogenomics education. Additionally, continuing education programs at various pharmacy conferences provide opportunities for practicing pharmacist to keep abreast of the current trends. At most of these conferences, the pharmacists have opportunities to attend sessions devoted to general issues in pharmacogenomics. 11 In addition, other sources of CE are also available to pharmacists. These include local and state programs, journal articles, and self-guided study.
Pharmacy technicians should also be made aware of advances and how those advances could affect their role. This could be achieved either through CE credits for technicians or by training pharmacists through educational workshops to in turn train technicians. Colleges of Pharmacy and national pharmacy organizations should recognize the need for such programs and develop workshops or CE credits accordingly.
More information regarding the HGP can be obtained from the following web site: http://www.genome.gov. In addition there are several educational sites on the World Wide Web from which the pharmacist can obtain more information about genomics. A recently published book, entitled, Pharmacogenomics, edited by Werner Kalow, Urs Meyers, and Rachel Tyndale, might interest pharmacists. This book covers the area of pharmacogenomics, from technology development to its impact on clinical medicine and diagnostics. 33 
Limitations
There are some limitations to this study that one should consider before applying the results. The subjects were recruited using a convenient sampling process rather than a random selection process. However, the sample size was sufficient to reduce biases that would have arisen due to the sampling process. In addition, a frequency distribution analysis based on the zip code indicated an adequate representation of the sample in the area.
The measurements of the study variables were subjective and hence interpretation by the subjects may be different with time as pharmacist gain more knowledge on such topics. The applications of the HGP are broad and its long-term impact not yet known. Although theoretically the use of pharmacogenomic information may revolutionize drug delivery, practically there are only a few examples of this occurring. Therefore, the participants may not have had sufficient exposure to pharmacogenetics in their practice to provide meaningful and/or insightful responses. Lastly, only community pharmacists were surveyed. Other groups, such as institutional pharmacists, may have more exposure to such topics since most of the studies dealing with pharmacogenomics are currently at their infancy stages and undergoing testing only in hospital settings.
CONCLUSIONS
Clearly, community pharmacists lack knowledge regarding advances in the HGP, genetic testing, and pharmacogenomics. Various organizations should make an effort to provide more specific and specialized CE programs in this area. In addition, a mandatory workshop to help understand the techniques and skills required to dispense products that require special storage conditions should be developed. Furthermore, all colleges of pharmacy across the nation should start incorporating such information in their curriculums.
